Our purpose
We aim to optimize treatment and outcome of mycobacterial diseases, including tuberculosis (TB), the leading infectious disease killer worldwide. In settings where tuberculosis incidence is reducing, opportunistic infections with non-tuberculous mycobacteria (NTM) are emerging.